BDBM280974 4-Amino-2-[6-fluoro-1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methyl-5-[3-(1H-tetrazol-5-yl)phenyl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one::US10030027, Example 249B
SMILES: CC1(C(=O)Nc2nc(nc(N)c12)-c1nn(Cc2ccccc2F)c2cc(F)ccc12)c1cccc(c1)-c1nn[nH]n1
InChI Key:
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guanylate cyclase soluble subunit alpha-1 (Homo sapiens (Human)) | BDBM280974 (4-Amino-2-[6-fluoro-1-(2-fluorobenzyl)-1H-indazol-...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.0680 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi... | US Patent US10030027 (2018) BindingDB Entry DOI: 10.7270/Q22N549C | |||||||||||
More data for this Ligand-Target Pair |